FSA Wealth Management LLC Purchases New Shares in Becton, Dickinson and Company (NYSE:BDX)

FSA Wealth Management LLC acquired a new position in shares of Becton, Dickinson and Company (NYSE:BDX) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 241 shares of the medical instruments supplier’s stock, valued at approximately $58,000.

Other institutional investors also recently bought and sold shares of the company. WR Wealth Planners LLC increased its stake in Becton, Dickinson and Company by 1.4% during the second quarter. WR Wealth Planners LLC now owns 2,978 shares of the medical instruments supplier’s stock worth $696,000 after acquiring an additional 42 shares during the last quarter. Clear Creek Financial Management LLC increased its position in Becton, Dickinson and Company by 5.1% during the 2nd quarter. Clear Creek Financial Management LLC now owns 900 shares of the medical instruments supplier’s stock worth $210,000 after purchasing an additional 44 shares in the last quarter. Sound Income Strategies LLC raised its holdings in Becton, Dickinson and Company by 35.8% in the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 44 shares during the period. Central Pacific Bank Trust Division lifted its position in Becton, Dickinson and Company by 22.5% during the third quarter. Central Pacific Bank Trust Division now owns 245 shares of the medical instruments supplier’s stock valued at $59,000 after buying an additional 45 shares in the last quarter. Finally, Tompkins Financial Corp lifted its position in Becton, Dickinson and Company by 44.2% during the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 46 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock opened at $221.90 on Monday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.17 and a quick ratio of 0.74. The company’s fifty day moving average price is $234.16 and its two-hundred day moving average price is $234.10. The firm has a market capitalization of $64.14 billion, a P/E ratio of 37.36, a P/E/G ratio of 1.65 and a beta of 0.43. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $249.89.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, topping the consensus estimate of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The business had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same quarter in the previous year, the firm posted $3.42 earnings per share. The company’s revenue was up 6.9% compared to the same quarter last year. On average, research analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 31st. Investors of record on Monday, December 9th will be paid a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.87%. The ex-dividend date of this dividend is Monday, December 9th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. Becton, Dickinson and Company’s payout ratio is 63.97%.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Evercore ISI lifted their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Finally, Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their target price for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $283.00.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.